The role of platelet-activating factor (PAF) and the efficacy of ABT- 491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 83-88

  Albert, Daniel H ^a   Malo, Peter E ^a   Tapang, Paul ^a   Shaughnessy, Thomas K ^a   Morgan, Douglas W ^a   Wegner, Craig D ^a   Curtin, Michael L ^a   Sheppard, George S ^a   Xu, Lianhong ^a   Davidsen, Steven K ^a   Summers, James B ^a   Carter, George W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (N,N DIMETHYLCARBAMOYL) 4 ETHYNYL 3 (3 FLUORO 4 [(1H 2 METHYLIMIDAZO[4,5 C] PYRID 1 YL)METHYL]BENZOYL]INDOLE HYDROCHLORIDE; 1 [3 [5 (4 FLUOROPHENOXY) 2 FURYL] 1 METHYL 2 PROPYNYL] 1 HYDROXYUREA; ANTIHISTAMINIC AGENT; LIPOXYGENASE INHIBITOR; MEPYRAMINE; METHYSERGIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

AIRWAY RESISTANCE; ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; GUINEA PIG; MALE; NONHUMAN; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHINORRHEA;

AIRWAY RESISTANCE; ANIMALS; CAPILLARY PERMEABILITY; GUINEA PIGS; HYPERSENSITIVITY; IMIDAZOLES; INDOLES; MALE; PLATELET ACTIVATING FACTOR; RATS; RATS, INBRED BN; RHINITIS;

EID: 15644370954     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Albert D, Magoc T, Tapang P, Luo G, Morgan D, Curtin M, Sheppard G, Xu L, Heyman H, Davidsen S, Summers J and Carter G (1997) Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. Eur J Pharmacol 325:69-80.
2. Andersson M and Pipkom U (1988) The effect of platelet-activating factor on nasal hyperresponsiveness. Eur J Clin Pharmacol 35:231-235.
3. Belser RBJ, Fine ED and Boehm KD (1996) Role of tumor necrosis factor and granulocyte-macrophage colony-stimulating factor in the late allergic response in human nasal mucosa. Otolaryngol Head Neck Surg 114:418-423.
4. Braquet P, Touqui L, Shen TY and Vargaftig BB (1987) Perspectives in plateletactivating factor research. Pharmacol Rev 39:97-145.
5. Brooks CDW, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C, Harris RR, Malo PE, Carter GW and Bell RL (1995) ABT-761, R (+) N-3-[5-(4-Fluorophenylmethyl)2-thienyl] -1-methyl-2-propynyl-N-hydroxyurea, a second generation 5-lipoxygenase inhibitor. J Med Chem 38:4768-4775.
6. Evans TW, Rogers DF, Aursudkij B, Chung KF and Barnes PJ (1988) Inflammatory mediators involved in antigen-induced airway microvascular leakage in guineapigs. Am J Respir Crit Care Med 138:395-399.
7. Evans TW, Rogers DF, Aursudkij B, Chung KF and Barnes PJ (1989) Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig. Clin Sci 76:479-485.
8. Garrelds IM, Veld CG, van Wijk RG and Zijlstra FJ (1996) Nasal hyperreactivity and inflammation in allergic rhinitis. Mediators Inflammation 5:79-94.
9. Herxheimer H (1952) Repeatable microshocks of constant strength in guinea pig anaphylaxis. J Physiol 117:251-255.
10. Horvath CJ, Kaplan JE and Malik AB (1991) Role of platelet-activating factor in mediating tumor necrosis factor alpha-induced pulmonary vasoconstriction and plasma-lymph protein transport. Am Rev Respir Dis 144:1337-1341.
11. Hotchkiss JA, Stam MA and Harkema JR (1993) Platelet-activating factor stimulates rapid mucin secretion in rat nasal airways in vivo. Exp Lung Res 19:545-557.
12. Howarth PH, Harrison K, Lau LCK, Dube L and Cohn J (1993) The influence of the 5-lipoxygenase inhibitor A-78773 on the nasal response to allergen in rhinitis. J Allergy Clin Immunol 93:297A.
13. Hwang SB, Li CL, Lam MH and Shen TY (1985) Characterization of cutaneous vascular permeability induced by PAF in guinea pigs and rats and its inhibition by PAF receptor antagonists. Lab Invest 52:617-630.
14. Knapp HR (1990) Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 327:1745.
15. Krause H (1995) Pharmacotherapy of perennial and seasonal allergic rhinitis. Clin Immunother 3:308-324.
16. Kyriacopoulos F, Boichot E, Lagente V, Mencia-Huerta JM and Braquet P (1995) Role of PAF in the late airway microvascular leakage induced by antigen in IgE-sensitized rat. Fundam Clin Pharmacol 9:350-356.
17. Labrakis-Lazana K, Lazanas M, Koussissis S, Tournis S and Demopoulos C (1988) PAF of biological fluids in disease: blood levels in allergic rhinitis. Haematologica 73:379-382.
18. Leggieri E, Tedeshi A, Lorini M, Bianco A and Miadonna A (1991) Study of the effects of PAF on human nasal airways. Allergy 46:466-471.
19. Malo PE, Bell RL, Shaughnessy TK, Summers JB, Brooks DW and Carter GW (1994) The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm Pharmacol 7:73-79.
20. Meltzer EO (1995) An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 95:1097-1110.
21. Miadonna A, Milazzo M, Lorini M, Sala A and Tedeschi A (1996) Nasal neutrophil and release of myeloperoxidase induced by nasal challenge with platelet-activating factor: different degrees of responsiveness in atopic and nonatopic subjects. J Allergy Clin Immunol 97:947-954.
22. Miadonna M, Tedeshi A, Arnoux B, Sala A, Zanussi C and Benveniste J (1989) Evidence of PAF metabolic pathway activation in antigen challenge of upper respiratory airways. Am Rev Respir Dis 140:142-147.
23. Misawa M and Iwamura S (1990) Platelet-activating factor (PAF)-induced rhinitis and involvement of PAF in allergic rhinitis in guinea pigs. Jpn J Pharmacol 54:217-226.
24. Mizuno H, Kawamura Y, Iwase N and Ohno H (1991) Effects of flutropium on experimental models of drug- and allergy-induced rhinitis in guinea pigs. Jpn J Pharmacol 55:321-328.
25. Naclerio RM, Baroody FM and Togias AG (1991) The role of leukotrienes in allergic rhinitis: a review. Am Reu Respir Dis 143:91-95.
26. Nan ta S and Asakura K (1993) The effects of anti-PAF and other agents on the nasal symptoms in sensitized guinea pigs. Auris Nasus Larynx 20:175-183.
27. Nonaka M, Nonaka R, Jordana M and Dolovich J (1996) GM-CSF, IL-8, IL-1R, TNF-aR, and HLA-DR in nasal epithelial cells in allergic rhinitis. Am J Respir Crit Care Med 153:1675-1681.
28. Seeds EAM, Kilfeather S, Okiji S, Schoupe TS, Donigi-Gale D and Page CP (1995) Role of lipoxygenase metabolites in platelet-activating factor- and antigen-induced bronchial hyperresponsiveness and eosinophil infiltration. Eur J Pharmacol 293: 369-376.
29. Shirasaki H and Asakura K (1990) Detection of PAF in nasal lavage fluid from patients with and experimental animals with nasal allergy. J Otolaryngol Jpn 93:420-427.
30. Summers JB and Albert DH (1995) Platelet-activating factor antagonists, in Advances in Pharmacology (August JT, Anders MW, Murad F, and Coyle J eds) PP 67-168, Academic Press, San Diego.
31. Summers JBJ, Davidsen SK, Curtin ML, Heyman HR, Sheppard GS, Carrera GMJ and Garland RB (1996) Platelet-activating factor antagonists: imidazopyridine indoles. Micro Patent, Abbott Laboratories, Abbott Park, IL, 59.
32. Takahashi N, Aramaki Y and Tsuchiya S (1990) Allergic rhinitis model with Brown Norway rat and evaluation of antiallergic drugs. J Pharmacobio-Dyn 13:414-420.